Big Pharma M&A Ignites In Vivo CAR-T Race, Heralding New Era of 'One-Shot' Cancer Therapy

Major pharmaceutical companies are making multi-billion dollar acquisitions, signaling a strategic pivot towards 'in vivo CAR-T' technology, which creates therapeutic cells directly inside the patient's body.

This shift is driven by the high costs and complex manufacturing of existing 'ex vivo' therapies, coupled with promising clinical results for CAR-T in treating autoimmune diseases, opening up a vast new market.

Consequently, in vivo CAR-T is being hailed as a potential 'game changer' that could make revolutionary cell therapies more affordable, accessible, and potentially safer for a wider range of patients.

The narrative of 'in vivo CAR-T' therapy as a game changer has rapidly solidified in recent weeks.

This momentum was primarily sparked by two massive deals in February 2026. First, Eli Lilly announced its acquisition of Orna Therapeutics, a company developing in vivo CAR-T using circular mRNA, for up to $2.4 billion. Shortly after, Gilead revealed plans to buy Arcellx for up to $7.8 billion, strengthening its position in cell therapy. These back-to-back acquisitions by industry giants sent a clear signal: the future of cell therapy is shifting from the complex, external manufacturing process ('ex vivo') to a streamlined, 'one-shot' approach that engineers cells directly inside the body ('in vivo').

However, this shift didn't happen in a vacuum. The groundwork was laid over the past year. Pharmaceutical leaders like BMS and AbbVie had already made significant investments in in vivo platforms, indicating a growing trend. Furthermore, promising clinical data has shown that CAR-T therapy can be highly effective not just for blood cancers, but also for autoimmune diseases like lupus. This potential to 'reset' the immune system has opened up a market far larger than oncology, making the development of a more scalable therapy an urgent priority.

Two fundamental drivers are accelerating this transition. The first is the prohibitive economics and logistics of current ex vivo CAR-T therapies. With price tags up to $465,000 and a manufacturing process that takes about a month per patient, these treatments are accessible to only a few. The in vivo approach promises a more 'off-the-shelf' solution, drastically cutting costs and wait times. The second driver is safety. In 2024, the FDA mandated a 'boxed warning' for existing CAR-T products due to risks of secondary cancers. This regulatory pressure has increased the appeal of newer mRNA-based in vivo methods, which are designed to be temporary and do not permanently alter a cell's DNA, potentially offering a better safety profile.

In essence, the convergence of major M&A, market expansion into autoimmune diseases, and the push for a more affordable and safer alternative has created a perfect storm. It's this combination of factors that has firmly established in vivo CAR-T as the next frontier in medicine.

Glossary
CAR-T Therapy: A type of immunotherapy where a patient's T-cells (a type of immune cell) are modified to recognize and attack cancer cells.
In vivo / Ex vivo: 'In vivo' (Latin for 'within the living') means a medical procedure is done inside the body. 'Ex vivo' ('outside the living') means cells are removed, treated externally, and then returned to the body.
mRNA: Messenger RNA is a molecule that carries genetic instructions from DNA to the cell's machinery for making proteins. In these new therapies, it's used to temporarily program T-cells.

Big Pharma M&A Ignites In Vivo CAR-T Race, Heralding New Era of 'One-Shot' Cancer Therapy

The narrative of 'in vivo CAR-T' therapy as a game changer has rapidly solidified in recent weeks.

Glossary
CAR-T Therapy: A type of immunotherapy where a patient's T-cells (a type of immune cell) are modified to recognize and attack cancer cells.
In vivo / Ex vivo: 'In vivo' (Latin for 'within the living') means a medical procedure is done inside the body. 'Ex vivo' ('outside the living') means cells are removed, treated externally, and then returned to the body.
mRNA: Messenger RNA is a molecule that carries genetic instructions from DNA to the cell's machinery for making proteins. In these new therapies, it's used to temporarily program T-cells.